Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Akamai Technologies heads into its November 3 earnings with a notable tension at its core: short sellers hold a large position but are quietly trimming, while analysts cluster around hold ratings well below the current price target consensus.
Short interest remains elevated at 13.3% of the free float, roughly 19.1 million shares, but the direction has turned. The position has fallen about 0.4% over the past week and 2.3% over the past month, a steady unwinding rather than a decisive exit. The borrow market is loose enough to reinforce that read. Availability has actually widened to 294% of short interest, meaning roughly three shares are available to borrow for every one already lent out. Cost to borrow ticked up 14% on the week to 0.52%, still a negligible figure for a name carrying this level of short interest. There is no squeeze pressure here. The ORTEX short score has edged down slightly to 62, consistent with mild reduction in bearish conviction. Options traders are offering no additional signal; the put/call ratio at 0.30 is essentially flat against its 20-day average of 0.29, well below the 52-week high of 0.71 reached earlier in the year.
The Street picture is more divided than the bare consensus rating of "hold" suggests. A cluster of analyst actions followed the stock's late September move. Piper Sandler raised its target sharply to $158 from $125, reiterating Overweight. JP Morgan lifted its target to $167 from $158, staying Neutral. DA Davidson cut its target to $150 from $185 while holding Buy, the most notable directional signal of the group: a bull firm trimming by $35. UBS and TD Cowen both raised targets modestly from more cautious positions. Guggenheim took the most aggressive stance, lifting to $225 from $190. Against a current price of $108.62, the mean analyst target of $159 implies roughly 46% upside on paper, but with the consensus lodged at hold and a range running from $135 to $225, the Street is essentially saying the Anthropic deal changes the long-term math while the near-term execution is unproven. Forward earnings revisions tell a striking story: the 12-month forward EPS growth rank sits at the 97th percentile, the highest signal in the factor score set. EPS momentum over 90 days scores only 18, so analysts are upgrading the long-run estimate while remaining guarded about the near term. The dividend score of 71 is a minor bright spot; EV/EBITDA of 9.6 is down modestly over 30 days, the multiple compressing slightly as the stock has recovered.
The bull and bear cases map cleanly onto the Anthropic AI infrastructure deal announced earlier this year. Bulls point to an $11.6 billion, seven-year commitment from Anthropic, potentially expanding to $20 billion, which adds an estimated $14.4 billion of cloud contract value for 2026 and could support around $2.2 billion of annual recurring revenue at maturity. The implied IRR of roughly 15% clears the company's estimated 9.5% WACC. Bears counter that management has guided for no revenue from the deal in 2026 alongside roughly $5.5 billion of capex, and that the CDN core faces about 15% annual price compression. The capital efficiency looks thin: approximately $0.30 of ARR per dollar of capex spent, at an estimated $75 to $80 million per megawatt of compute capacity.
Retail attention has spiked. The ORTEX alt data layer shows a Wikipedia views z-score of 4.3 as of mid-September, a multi-standard deviation reading indicating sharply above-average online interest in the company relative to its own 90-day baseline. This is an attention signal, not a revenue indicator, and no alt data dataset for Akamai has been measured to lead its reported figures. The November 3 print is 27 days away.
Institutional ownership has shifted in ways worth noting. Capital Research and Management, the largest disclosed holder, added 4.46 million shares in a recent filing to reach 7.88% of outstanding stock. BlackRock added 1.3 million shares and now holds 7.28%. Both Vanguard entities are reporting relatively stable positions. No Schedule 13D activist filing is on record, and all large holders are reporting passive stakes. Insider activity over the past 90 days has been a net negative in dollar terms: three senior EVP-level sales totaling roughly $1.86 million, all executed under pre-arranged 10b5-1 plans, which reduces the informational weight of those transactions considerably.
The last earnings print, on August 6, dropped the stock nearly 10% the next day before it recovered most of that ground over the following week, a pattern worth carrying into the November 3 setup. With shorts trimming but still at 13% of float, and the AI infrastructure thesis unproven in the revenue line, the key question heading into next month is whether management provides any quantification of the Anthropic ramp timeline.
See the live data behind this article on ORTEX.
Open AKAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
